On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Rates of depression and stress-related disorders rise among new fathers a year after birth, even though they have fewer ...

What is Deep Brain Stimulation for depression? Discover how the TRANSCEND trial at UT Southwestern is using "brain pacemakers" to treat treatment-resistant depression by targeting neural communication ...

People with depression tend to prefer carbohydrate-rich foods, according to a new study published in Psychological Medicine. The findings point toward the possibility of dietary therapies for ...

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...

Flow's FL-100 device is expected to be available in the US as soon as Q2 2026. Image credit: Tada Images via Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Flow Neuroscience’s ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire Intra-Cellular Therapies, a company whose main asset has the potential to ...